Cargando…

(18)F-FDG-PET hypometabolism as a predictor of favourable outcome in epilepsy surgery: protocol for a systematic review and meta-analysis

INTRODUCTION: A substantial proportion of patients who undergo surgery for drug resistant focal epilepsy do not become seizure free. While some factors, such as the detection of hippocampal sclerosis or a resectable lesion on MRI and electroencephalogram-MRI concordance, can predict favourable outco...

Descripción completa

Detalles Bibliográficos
Autores principales: Courtney, Merran R, Antonic-Baker, Ana, Sinclair, Benjamin, Nicolo, John-Paul, Neal, Andrew, Law, Meng, Kwan, Patrick, O'Brien, Terence J, Vivash, Lucy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540844/
https://www.ncbi.nlm.nih.gov/pubmed/36202585
http://dx.doi.org/10.1136/bmjopen-2022-065440
Descripción
Sumario:INTRODUCTION: A substantial proportion of patients who undergo surgery for drug resistant focal epilepsy do not become seizure free. While some factors, such as the detection of hippocampal sclerosis or a resectable lesion on MRI and electroencephalogram-MRI concordance, can predict favourable outcomes in epilepsy surgery, the prognostic value of the detection of focal hypometabolism with (18)F-fluorodeoxyglucose positive emission tomography ((18)F-FDG-PET) hypometabolism is uncertain. We propose a protocol for a systematic review and meta-analysis to examine whether localisation with (18)F-FDG-PET hypometabolism predicts favourable outcomes in epilepsy surgery. METHODS AND ANALYSIS: A systematic literature search of Medline, Embase and Web of Science will be undertaken. Publications which include evaluation with (18)F-FDG-PET prior to surgery for drug resistant focal epilepsy, and which report ≥12 months of postoperative surgical outcome data will be included. Non-human, non-English language publications, publications with fewer than 10 participants and unpublished data will be excluded. Screening and full-text review of publications for inclusion will be undertaken by two independent investigators, with discrepancies resolved by consensus or a third investigator. Data will be extracted and pooled using random effects meta-analysis, with heterogeneity quantified using the I(2) analysis. ETHICS AND DISSEMINATION: Ethics approval is not required. Once complete, the systematic review will be published in a peer-reviewed journal. PROSPERO REGISTRATION NUMBER: CRD42022324823.